ĐÁNH GIÁ HIỆU QUẢ CỦA PHÁC ĐỒ ACRIPTEGA TRONG NĂM ĐẦU TIÊN TRÊN NGƯỜI NHIỄM HIV CHƯA TỪNG ĐIỀU TRỊ ARV

Abstract

Objectives: We conducted the project " Effectiveness of Acriptega in the first year in naïve people living with HIV” with two objectives: To evaluate the effectiveness of the Acriptega regimen in. antiretroviral therapy and find out some side effects appeared in the first 12 months.

Result and conclusions: Our study recruited 77 qualified patients, 72.8% male, average age was 39.9 years old, average weight was 56.2 kg. Heterosexual transmission is 79.2%, Clinical stage 3 and 4  were  28.6%, HBsAg positive rate was 18.4%, HCV Ab positive rate was 3.9%. The mean CD4 count was 175.6 cells/mm3. 48.6% patients with  CD4 count was less than 100 cells/mm³. After 6th month, 64 patients remained and 53 patients were followed up at 12^th month. 100% of patients returned to clinical stage 1, the CD4 cell count increased more 162 cells/mm3 compared with the initial time with p<0.05 at the 6^th month.  The rate of undetectable HIV viral load cases  recorded   at 78.2% at  6^th month, 92.1% at 12^th month, with statistical significance (p<0.05), there were no cases of treatment failure. The initial HIV viral load cases which were  more than 100,000 copies/mL was reduced at undetectable viral load level  with  rate 62,1% , 100% cases  after 6^th and 12th month respectively. Side effects: after 12 months of treatment Acriptega  such as Average weight gain of study’s cases was 3.1 kg with p<0.05. The blood cholesterol index also was  increased from 8.9% to 26.7% with p<0.5%.